Seres Therapeutics Inc (MCRB) Receives Consensus Recommendation of “Buy” from Brokerages
Seres Therapeutics Inc (NASDAQ:MCRB) has been given an average recommendation of “Buy” by the twelve brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $18.25.
MCRB has been the topic of a number of recent analyst reports. Cantor Fitzgerald restated a “buy” rating on shares of Seres Therapeutics in a report on Wednesday, August 30th. Seaport Global Securities restated a “buy” rating and set a $20.00 price target on shares of Seres Therapeutics in a report on Friday, October 6th. Cowen restated a “buy” rating on shares of Seres Therapeutics in a report on Monday, October 2nd. Zacks Investment Research upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Tuesday, December 5th. Finally, CIBC initiated coverage on shares of Seres Therapeutics in a report on Friday, October 13th. They set an “outperform” rating and a $19.00 price target on the stock.
Shares of Seres Therapeutics (NASDAQ:MCRB) opened at $10.47 on Thursday. Seres Therapeutics has a 1-year low of $8.85 and a 1-year high of $17.42. The company has a current ratio of 6.53, a quick ratio of 6.53 and a debt-to-equity ratio of 0.11.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC bought a new stake in Seres Therapeutics in the third quarter worth approximately $170,000. Perceptive Advisors LLC bought a new stake in Seres Therapeutics in the third quarter worth approximately $2,165,000. Schwab Charles Investment Management Inc. grew its position in Seres Therapeutics by 12.8% in the third quarter. Schwab Charles Investment Management Inc. now owns 103,286 shares of the biotechnology company’s stock worth $1,657,000 after acquiring an additional 11,743 shares in the last quarter. Schroder Investment Management Group bought a new stake in Seres Therapeutics in the third quarter worth approximately $1,088,000. Finally, JPMorgan Chase & Co. grew its position in Seres Therapeutics by 39.9% in the third quarter. JPMorgan Chase & Co. now owns 373,334 shares of the biotechnology company’s stock worth $6,160,000 after acquiring an additional 106,479 shares in the last quarter. 75.94% of the stock is currently owned by hedge funds and other institutional investors.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.